Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's lymphoma study group

被引:205
作者
Behringer, K
Breuer, K
Reineke, T
May, M
Nogova, L
Klimm, B
Schmitz, T
Wildt, L
Diehl, V
Engert, A
机构
[1] Univ Hosp Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] German Hodgkin Lymphoma Study Grp, Cologne, Germany
[3] Univ Innsbruck, Dept Gynecol Endocrinol & Reprod Med, A-6020 Innsbruck, Austria
关键词
D O I
10.1200/JCO.2005.08.138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Long-term survivors of successfully treated Hodgkin's lymphoma (HL) are at risk for late complications. Among these, infertility for female patients is of major importance. The subject of this analysis is to evaluate the menstrual status after HL therapy. Patients and Methods From 1994 to 1998, the German Hodgkin's Lymphoma Study Group conducted clinical trials for early-, intermediate-, and advanced-stage HL (trials HD7 to HD9) involving a total of 3,186 patients. A survey was carried out to evaluate the menstrual status after therapy. The following factors were assessed concerning their influence on amenorrhea: age, treatment, stage, and the use of oral contraceptives during chemotherapy. Results A total of 405 women aged younger than 40 years answered the study questions. After a median follow-up of 3.2 years, 51.4% of the women receiving eight cycles of dose-escalated bleomycin etoposide doxorubicin cyclophosphamide vincristine procarbazine and prednisone (BEACOPP) had continuous amenorrhea. Amenorrhea was significantly more frequent after dose-escalated BEACOPP compared with doxorubicin, bleomycin, vinblastine, and dacarbazine; cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine; or standard BEACOPP (P = .0066). Amenorrhea after therapy was most pronounced in women with advanced-stage HL (P < .0001), in women older than 30 years at treatment (P = .0065), and in women who did not take oral contraceptives during chemotherapy (P = .0002). Conclusion Most women who are treated for advanced-stage HL experience amenorrhea after therapy. Amenorrhea is significantly more frequent in women with advanced-stage HL receiving eight cycles of dose-escalated BEACOPP and in women older than 30 years at first treatment. Furthermore, the data show a statistical association between the use of oral contraceptives and return of menstrual cycle, which is subject to further investigation.
引用
收藏
页码:7555 / 7564
页数:10
相关论文
共 49 条
  • [1] ANDRES J, 1997, ANN MATH SIL, V11, P39
  • [2] High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the late effects study group
    Bhatia, S
    Yasui, Y
    Robison, LL
    Birch, JM
    Bogue, MK
    Diller, L
    DeLaat, C
    Fossati-Bellani, F
    Morgan, E
    Oberlin, O
    Reaman, G
    Ruymann, FB
    Tersak, J
    Meadows, AT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4386 - 4394
  • [3] Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
    Bines, J
    Oleske, DM
    Cobleigh, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) : 1718 - 1729
  • [4] Blatt J, 1999, MED PEDIATR ONCOL, V33, P29, DOI 10.1002/(SICI)1096-911X(199907)33:1<29::AID-MPO6>3.0.CO
  • [5] 2-2
  • [6] Fertility after treatment for Hodgkin's disease
    Blumenfeld, Z
    Dann, E
    Avivi, I
    Epelbaum, R
    Rowe, JM
    [J]. ANNALS OF ONCOLOGY, 2002, 13 : 138 - 147
  • [8] Brusamolino E, 2000, HAEMATOLOGICA, V85, P1032
  • [9] Byrne J, 1999, MED PEDIATR ONCOL, V33, P24
  • [10] EARLY MENOPAUSE IN LONG-TERM SURVIVORS OF CANCER DURING ADOLESCENCE
    BYRNE, J
    FEARS, TR
    GAIL, MH
    PEE, D
    CONNELLY, RR
    AUSTIN, DF
    HOLMES, GF
    HOLMES, FF
    LATOURETTE, HB
    MEIGS, JW
    STRONG, LC
    MYERS, MH
    MULVIHILL, JJ
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (03) : 788 - 793